Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.

• Informed Consent signed by the subject

Locations
Other Locations
Switzerland
Lausanne University Hospital
RECRUITING
Lausanne
Contact Information
Primary
Naik Vietti Violi, MD
naik.vietti-violi@chuv.ch
+41213144556
Backup
Clarisse Dromain, MD
Clarisse.dromain@chuv.ch
+41213144556
Time Frame
Start Date: 2023-04-01
Estimated Completion Date: 2027-04-30
Participants
Target number of participants: 330
Treatments
Experimental: HCC screening population according to European Association for the Study of the Liver recommendation
Related Therapeutic Areas
Sponsors
Leads: Naik Vietti Violi

This content was sourced from clinicaltrials.gov